LP’s hydrocodone bitartrate tablet (HYD) is undergoing “priority review” by the (), the company
recently announced.
Reports said the tablet, if approved, will be the first painkiller with an “abuse-deterrent formula.” Such a formula will make it harder for the drug to be crushed or liquefied so it may be snorted or injected by drug abusers.
pointed out that the only gives priority review to new drugs that propose significant and improvement to the safety and effectiveness of existing drugs.
"This is another milestone in our effort to offer patients and health professionals a portfolio of pain medications with abuse-deterrent technology," Mark Timney, President and of , was quoted saying.
Todd Baumgartner, , MPH, Vice President of Regulatory Affairs and chief medical officer of said that if approved by the FDA, the tablet “will be a valuable therapy for treating chronic pain.”
Read more: http://www.benzinga.com/14/07/4716634/fda-prioritizes-review-of-abuse-deterrent-painkiller#ixzz388wHoBnj
recently announced.Reports said the tablet
, if approved, will be the first painkiller with an “abuse-deterrent formula.” Such a formula will make it harder for the drug to be crushed or liquefied so it may be snorted or injected by drug abusers.pointed out that the only gives priority review to new drugs that propose significant and improvement to the safety and effectiveness of existing drugs.
"This is another milestone in our effort to offer patients and health professionals a portfolio
of pain medications with abuse-deterrent technology," Mark Timney, President and of , was quoted saying.Todd Baumgartner, , MPH, Vice President of Regulatory Affairs and chief medical officer of said that if approved by the FDA, the tablet “will be a valuable therapy for treating chronic pain.”
Read more: http://www.benzinga.com/14/07/4716634/fda-prioritizes-review-of-abuse-deterrent-painkiller#ixzz388wHoBnj
No comments:
Post a Comment